成人噬血细胞综合征诊断与治疗进展

王昭; 王晶石

doi:10.13201/j.issn.1004-2806.2022.01.001

成人噬血细胞综合征诊断与治疗进展

王昭^1, ,,
王晶石¹

- 首都医科大学附属北京友谊医院血液科(北京，100050)
基金项目:
国家自然科学基金(No：81871633)；北京市自然科学基金(No：7181003)；首都卫生发展科研专项重点攻关项目(No：首发2020-1-2022)；北京市医管局“登峰”人才培养计划(No：DFL20180101)

详细信息

作者简介:
专家简介：王昭，主任医师/教授，博士生(后)导师，首都医科大学附属北京友谊医院血液内科主任。担任国际组织细胞协会噬血细胞综合征执行委员，中国医师协会血液科医师分会组织细胞疾病专业委员会主任委员，中华医学会血液学分会淋巴细胞疾病学组副组长，中国免疫学会血液免疫分会常委，中国抗癌协会淋巴瘤专业委员会常委，中国抗癌协会血液病转化医学专业委员会常委，中国老年学学会老年肿瘤专业委员会淋巴血液肿瘤分委会常委，中国妇幼保健协会脐带血临床应用专业委员会常委，海峡两岸医药卫生交流协会血液病专家委员会常委、总干事长，北京市医管局扬帆计划重点专业团队负责人、登峰人才团队负责人。主持噬血细胞综合征中国专家共识的制定并参与噬血细胞综合征国际指南的制定，以第一完成人分别获得中华医学科技奖二等奖、华夏医学科技二等奖、北京医学科技二等奖、“金桥奖”二等奖、北京市科学技术三等奖。主编《噬血细胞综合征》、《组织细胞疾病》专著，担任《中华血液学杂志》、《中华医学杂志》、《中国实验血液学杂志》、《白血病·淋巴瘤》、《临床内科杂志》等编委，Haematologica、British Journal of Haematology、Orphanet Journal of Rare Diseases等国际期刊审稿人

通讯作者: 王昭，E-mail：wangzhao@ccmu.edu.cn

中图分类号: R55

收稿日期: 2021-11-09

刊出日期: 2022-01-01

Progress in diagnosis and treatment of hemophagocytic syndrome in adults

WANG Zhao^1, ,,
WANG Jingshi¹

More Information

Corresponding author: WANG Zhao, E-mail: wangzhao@ccmu.edu.cn

Received Date: 09 November 2021

Publish Date: 01 January 2022

摘要

- 噬血细胞综合征 /
- 成人 /
- 诊断 /
- 治疗
- hemophagocytic syndromes /
- adult /
- diagnosis /
- treatment

HTML全文

参考文献(33)

[1]	Farquhar JW, Claireaux AE. Familial Haemophagocytic Reticulosis[J]. Arch Dis Child, 1952, 27(136): 519-525. doi: 10.1136/adc.27.136.519
[2]	La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2019, 133(23): 2465-2477. doi: 10.1182/blood.2018894618
[3]	Ramachandran S, Zaidi F, Aggarwal A, et al. Recent advances in diagnostic and therapeutic guidelines for primary and secondary hemophagocytic lymphohistiocytosis[J]. Blood Cells Mol Dis, 2017, 64: 53-57. doi: 10.1016/j.bcmd.2016.10.023
[4]	Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis(HLH): A heterogeneous spectrum of cytokine-driven immune disorders[J]. Cytokine Growth Factor Rev, 2015, 26(3): 263-280. doi: 10.1016/j.cytogfr.2014.10.001
[5]	Henter JI, Horne A, Arico′ M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2): 124-131. doi: 10.1002/pbc.21039
[6]	噬血细胞综合征中国专家联盟, 中华医学会儿科学分会血液学组. 噬血细胞综合征诊治中国专家共识[J]. 中华医学杂志, 2018, 98(2): 91-95. doi: 10.3760/cma.j.issn.0376-2491.2018.02.004
[7]	Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes[J]. Blood, 2012, 119(12): 2754-2763. doi: 10.1182/blood-2011-08-374199
[8]	Lehmberg K, Ehl S. Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis[J]. Br J Haematol, 2013, 160(3): 275-287. doi: 10.1111/bjh.12138
[9]	Xu XJ, Tang YM, Song H, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children[J]. J pediatr, 2012, 60(6): 984-990.
[10]	Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome[J]. Arthritis Rheumatol, 2014, 66(9): 2613-2620. doi: 10.1002/art.38690
[11]	Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis(NACHO)[J]. Pediatr Blood Cancer, 2019, 66: e27929.
[12]	Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis(EBV-HLH); update 2010[J]. J Pediatr Hematol Oncol, 2011, 33(1): 35-39. doi: 10.1097/MPH.0b013e3181f84a52
[13]	Lehmberg K, Nichols KE, Henter JI, et al. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies copy[J]. Haematologica, 2015, 100(8): 997-1004.
[14]	Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key[J]. Open Access Rheumatol, 2018, 10: 117-128. doi: 10.2147/OARRR.S151013
[15]	Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation[J]. Blood, 2002, 100(7): 2367-2373. doi: 10.1182/blood-2002-01-0172
[16]	Trottestam H, Horne A, Aricò M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: longterm results of the HLH-94 treatment protocol[J]. Blood, 2011, 118(17): 4577-4584. doi: 10.1182/blood-2011-06-356261
[17]	Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study[J]. Blood, 2017, 130(25): 2728-2738. doi: 10.1182/blood-2017-06-788349
[18]	Wang Y, Huang W, Hu L, et al. Multi-center study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis[J]. Blood, 2015, 126(19): 2186-2192. doi: 10.1182/blood-2015-05-644914
[19]	Wang J, Wang Y, Wu L, et al. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis[J]. J Hematol Oncol, 2016, 9(1): 84. doi: 10.1186/s13045-016-0317-7
[20]	Wang J, Zhang R, Wu X, et al. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial[J]. Br J Haematol, 2021, 193(4): 761-768. doi: 10.1111/bjh.17331
[21]	王晶石, 王旖旎, 吴林, 等. 芦可替尼挽救治疗难治/复发噬血细胞综合征三例并文献复习[J]. 中华血液学杂志, 2019, 40(1): 74-76.
[22]	Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis[J]. Haematologica, 2020, 105(5): e210-e212. doi: 10.3324/haematol.2019.222471
[23]	Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis[J]. Blood, 2019, 134(21): 1783-1786. doi: 10.1182/blood.2019002289
[24]	Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis[J]. N Engl J Med, 2020, 382(19): 1811-1822. doi: 10.1056/NEJMoa1911326
[25]	Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab[J]. Pediatr Blood Cancer, 2013, 60(1): 101-109. doi: 10.1002/pbc.24188
[26]	Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra[J]. Nat Clin Pract Rheumatol, 2008, 4(11): 615-620. doi: 10.1038/ncprheum0919
[27]	Divithotawela C, Garrett P, Westall G, et al. Successful treatment of ctomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor-anakinra[J]. Respirol Case Rep, 2016, 4(1): 4-6. doi: 10.1002/rcr2.137
[28]	Chiossone L, Audonnet S, Chetaille B, et al. Protection from Inflammatory Organ Damage in a Murine Model of Hemophagocytic Lymphohistiocytosis Using Treatment with IL-18 Binding Protein[J]. Front Immunol, 2012, 3: 239-249.
[29]	Dufranc E, Del Bello A, Belliere J, et al. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome[J]. Crit Care, 2020, 24(1): 166. doi: 10.1186/s13054-020-02878-7
[30]	Marsh RA, Jordan MB, Talano JA, et al. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience[J]. Pediatr Blood Cancer, 2017, 64(4). doi:10.1002/pbc.26308.Epub 2016 Oct 27.
[31]	Liu P, Pan X, Chen C, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2020, 135(11): 826-833. doi: 10.1182/blood.2019003886
[32]	Thummalapalli R, Heumann T, Stein J, et al. Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma[J]. Case Rep Oncol, 2020, 13(2): 508-514. doi: 10.1159/000507281
[33]	Wang J, Wang Y, Wu L, et al. Splenectomy as a treatment for adults with relapsed hemophagocytic lymphohistiocytosis of unknown cause[J]. Ann Hematol, 2015, 94(5): 753-760. doi: 10.1007/s00277-014-2276-9